Key result
Acute heart failure in relatively young African adults carries ~21% 180-day mortality.
Why the study?
Contemporary data on the aetiology, management, and outcomes of acute heart failure across Africa are scarce.
Cohort (n=1,578)
Yes
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The study's strengths are the scale, geographical breadth, a pragmatic design suited to resource limited settings, and the first multi-country presentation-rate estimates for African acute heart failure. The project was a real team effort. I would thank all the investigators for the very time-consuming work, often in very difficult scenarios without any remuneration.”
“The study's strengths are the scale, geographical breadth, a pragmatic design suited to resource- limited settings, and the first multi-country presentation-rate estimates for African acute heart failure. The project was a real team effort. I would thank all the investigators for the very time-consuming work, often in very difficult scenarios without any remuneration.”
“PASCAR, the Cape Heart Institute and all the investigators across Africa are to be warmly congratulated for completing the region's largest and most detailed study of heart failure to date. The findings are incredibly important; they reveal what has and hasn't changed over time. Sadly, heart failure in Africa is still deadly and affects many young people of working age.”
Prospective cohort study observes aetiologies, clinical management, and mortality in acute heart failure across 17 African nations, highlighting crucial gaps in regional cardiovascular care.
BACKGROUND Contemporary data on the aetiology, management, and outcomes of acute heart failure across Africa are scarce. We aimed to conduct a contemporary assessment of acute heart failure aetiology, treatment patterns, presentation rates, and 180-day outcomes across Africa. METHODS THESUS-HF II was a prospective, multicentre, observational cohort study in 50 hospitals across 17 African countries. Adults aged 18 years or older with acute heart failure were enrolled during seven 24 h surveillance periods within an 8-week, site-specific window. Acute heart failure was identified by acute dyspnoea and congestion, supported by electrocardiography, chest radiography, and point-of-care echocardiography. We assessed presentation rates per 10 000 people in the adult catchment population per week, treatment patterns (including medication use at discharge), readmission, and all-cause mortality through to 180 days. This study was registered with the Pan African Clinical Trial Registry (PACTR202410553810557) and is completed; however, substudies are ongoing. FINDINGS Between July 1, 2024, and July 31, 2025, 1741 patients were assessed for eligibility at participating hospitals and 1578 were included in the study cohort. 793 (50·5%) of 1570 participants were female, 777 (49·5%) were male, and 1533 (97·8%) of 1567 were of African descent; median age was 56·0 years (IQR 40·0-69·0). The weekly acute heart failure presentation rate was 0·03 per 10 000 people (95% CI 0·02-0·05) overall and 0·02 per 10 000 people (0·01-0·04) for de novo acute heart failure. De novo acute heart failure accounted for 1007 (64·2%) of 1568 presentations. The leading aetiologies were hypertensive heart disease (576 [36·5%] of 1578), cardiomyopathy (370 [23·4%]), and ischaemic heart disease (367 [23·3%]). Median hospital ward stay was 6·0 days (IQR 4·0-10·0), and in-hospital mortality was 8·7% (95% CI 7·3-10·2; 134 of 1542 patients). At discharge, renin-angiotensin-aldosterone system inhibitors were prescribed in 1014 (73·9%) of 1373 patients, β blockers in 1053 (76·9%) of 1369 patients, mineralocorticoid receptor antagonists in 982 (71·9%) of 1366, and SGLT2 inhibitors in 743 (54·7%) of 1359; target doses were reached in fewer than half of patients. Of 1567 patients included in time-to-event analyses, 528 (33·7%) were lost to follow-up before 180 days. All-cause mortality was 11·1% (95% CI 9·6-12·9; 160 deaths) at 30 days and 20·6% (18·4-23·0; 255 deaths) at 180 days. All-cause mortality did not differ across aetiological groups over 30 days (log-rank p=0·39), but differed over 180 days (p=0·019). INTERPRETATION Compared with THESUS-HF, THESUS-HF II suggests an evolving aetiological profile of acute heart failure in Africa, although differences in ascertainment and diagnostic capability might have contributed to the apparent aetiological shift. High mortality in this relatively young cohort highlights the importance of heart failure prevention, access to cardiac care, guideline-directed therapy, and post-discharge follow-up. These findings suggest that short-term acute heart failure outcomes are not driven by its demographic, aetiological, and echocardiographic factors.
No takes yet. Share an insight, caveat, or question.
Sliwa et al. (2026) conducted a cohort in Acute heart failure (n=1,578). Acute heart failure was evaluated on All-cause mortality at 180 days (95% CI 18.4-23.0). Among 1,578 adults with acute heart failure across 17 African countries, 180-day all-cause mortality was 20.6%, highlighting high mortality in a relatively young cohort.
Synapse has enriched 10 related papers. Consider them for comparative context: